Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1141-1146

  Vincenzi, B ^a   Galluzzo, S ^a   Santini, D ^a   Rocci, L ^a   Loupakis, F ^b   Correale, P ^c   Addeo, R ^d   Zoccoli, A ^a   Napolitano, A ^a   Graziano, F ^e   Ruzzo, A ^f   Falcone, A ^c   Francini, G ^d   Dicuonzo, G ^a   Tonini, G ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d S Giovanni di Dio Hospital   (Italy)

^e SAN SALVATORE HOSPITAL   (Italy)

^f UNIVERSITY OF URBINO   (Italy)

Author keywords

Cetuximab; Colorectal cancer; Magnesium

Indexed keywords

CETUXIMAB; IRINOTECAN; MAGNESIUM; OXALIPLATIN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FEVER; GENE; GENE MUTATION; HUMAN; HYPOMAGNESEMIA; KRAS GENE; LOADING DRUG DOSE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN TOXICITY; TREATMENT OUTCOME; WILD TYPE;

EID: 79955505250     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq550     Document Type: Article

References (32)

1. Wolf FI, Maier JA, Nasulewicz A et al. Magnesium and neoplasia: from carcinogenesis to tumor growth and progression or treatment. Arch Biochem Biophys 2007; 458: 24-32.
2. Kumar BP, Shivakumar K, Kartha CC. Magnesium deficiency-related changes in lipid peroxidation and collagen metabolism in vivo in rat heart. Int J Biochem Cell Biol 1997; 29: 129-134.
3. Anastassopoulou J, Theophanides T. Magnesium-DNA interactions and the possible relation of magnesium to carcinogenesis. Irradiation and free radicals. Crit Rev Oncol Hematol 2002; 42: 79-91.
4. Rubin H. Central roles of Mg2+ and MgATP22- in the regulation of protein synthesis and cell proliferation: significance for neoplastic transformation. Adv Cancer Res 2005; 93: 1-58.
5. Lapidos KA, Woodhouse EC, Kohn EC, Masiero L. Mg(++)-induced endothelial cell migration: substratum selectivity and receptor-involvement. Angiogenesis 2001; 4: 21-28.
6. Rubin H. The logic of the membrane, magnesium, mitosis (MMM) model for the regulation of animal cell proliferation. Arch Biochem Biophys 2007; 458: 16-23.
7. Groenestege WM, Thebault S, van der Wijst J et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 2007; 117: 2260-2267.
8. Whang R, Hampton EM, Whang DD. Magnesium homeostasis and clinical disorders of magnesium deficiency. Ann Pharmacother 1994; 28: 220-226.
9. Schrag D, Chung KY, Flombaum C et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005; 97: 1221-1224.
10. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
11. Vincenzi B, Santini D, Rabitti C et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 2006; 94: 792-797.
12. Saltz LB, Meropol NJ, Loehrer PJ et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
13. Van Cutsem E, Kohne C-H, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Eng J Med 2009; 360: 1408-1417.
14. Lièvre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
15. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379.
16. Vincenzi B, Santini D, Galluzzo S et al. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res 2008; 14: 4219-4224.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Peto R, Pike MC, Armitage P et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39.
19. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187-220.
20. Tejpar S, Piessevaux H, Claes K et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol 2007; 8: 387-894.
21. Fakih MG, Wilding G, Lombardo J. Cetuximab induced hypomagnesemia in patients with colorectal cancer. Clin Colorectal Cancer 2006; 6: 152-156.
22. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
23. Janne PA, Engelman JA, Johnson BE et al. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005; 23: 3227-3234.
24. Tsuchihashi Z, Khambata-Ford S. Hanna N et al. Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 2005; 353: 208-209.
25. Bianco R, Garofalo S, Rosa R et al. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008; 98: 923-930.
26. Loupakis F, Ruzzo A, Cremolini C et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009; 101: 715-721.
27. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
28. Scartozzi M, Bearzi I, Pierantoni C et al. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 2007; 25: 3930-3935.
29. Frattini M, Saletti P, Romagnani E et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-1145.
30. Maier JAM, Nasulewicz-Goldeman A, Simonacci M et al. Insights into the mechanisms involved in magnesium-dependent inhibition of primary tumor growth. Nutr Cancer 2007; 59: 192-198.
31. Vincenzi B, Santini D, Russo A et al. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 2007; 4: 319-327.
32. Vincenzi B, Santini D, Russo A et al. Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann Oncol 2006; 17: 835-841.